- •In multivariate analysis, EMA had similar efficacy to EMACO for the treatment of GTN.
- •Time to remission for EMA and EMACO was similar.
- •Patients receiving EMA experienced greater toxicity, but this likely stemmed from lower rates of growth factor support.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Gestational trophoblastic neoplasia management: an update.Curr. Opin. Oncol. 2007; 19: 486-491
- Choriocarcinoma incidence in the United States.Am. J. Epidemiol. 1986; 123: 1094-1100
- Current management of gestational trophoblastic diseases.Gynecol. Oncol. 2009; 112: 654-662
- Update on the diagnosis and management of gestational trophoblastic disease.Int. J. Gynaecol. Obstet. 2018; 143: 79-85
- The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment.Int. J. Gynecol. Cancer. 2001; 11: 73-77
- Treatment of metastatic trophoblastic disease: good and poor prognosis.Am. J. Obstet. Gynecol. 1973; 115: 451-457
- Risk and prognostic factors in trophoblastic neoplasia.Cancer. 1976; 38: 1373-1385
- Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma.Am. J. Obstet. Gynecol. 1971; 109: 335-340
- Initital management of high-risk gestational trophoblastic neoplasia.in: Goff B. Dizon D.S. UptoDate. Wolters Kluwer, 2019 (November 12)
- Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.Gynecol. Oncol. 2003; 91: 552-557
- Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.Int. J. Gynecol. Cancer. 2006; 16: 1432-1438
- EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.Int. J. Gynecol. Cancer. 2008; 18: 357-362
- High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.J. Reprod. Med. 2012; 57: 231-236
- Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.J. Reprod. Med. 2006; 51: 767-772
- Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7.J. Reprod. Med. 2010; 55: 199-207
- EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.J. Clin. Oncol. 2013; 31: 280-286
- The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.Gynecol. Oncol. 1997; 64: 156-159
- Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.Gynecol. Oncol. 2000; 78: 28-31
- Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.Br. J. Cancer. 2000; 82: 1547-1552
- Conservative chemotherapy in gestational trophoblastic disease: experience with etoposide, methotrexate, and dactinomycin chemotherapy.Int. J. Gynecol. Cancer. 2016; 26: 790-795
- Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995–2010.J. Reprod. Med. 2014; 59: 7-12
- Anti-tumour activity of the epipodophyllin derivative VP16-213 (etoposide: NSC-141540) in gestational choriocarcinoma.Eur. J. Cancer. 1980; 16: 401-405
- The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.Cancer Chemother. Pharmacol. 1982; 7: 211-214
- Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979–1984).Br. J. Obstet. Gynaecol. 1986; 93: 63-69
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989.Br. J. Obstet. Gynaecol. 1991; 98: 550-557
- Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT −25 years experiences of KRI-TRD.Int. J. Gynaecol. Obstet. 1998; 60: S85-S96
- Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.Cochrane Database Syst. Rev. 2013; (CD005196): 1
- Preventing ovarian failure associated with chemotherapy.Med. J. Aust. 2018; 209: 412-416
- Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.J. Natl. Cancer Inst. 2006; 98: 890-896
- When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients.Gynecol. Oncol. 2019; 155: 8-12